Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: jack w garnes jr. who wrote (3967)	12/20/1997 9:28:00 PM
From: James Baker	Read Replies (2) \| Respond to of 23519

Jack Vivus is down from 40 to 9 and you ask "What's the big deal?" Although I areee with your major point that MUSE is a sellable, viable product and is insurance and VA covered and will soon be going international in UK and elsewhere. But if Barron's quotes a doc who is supposed to know something about ED but in fact has been a paid consultant or investigator for every other company in ED except Vivus and this is not acknowledged, then this is WRONG and can not go unanswered. Does Barrons care - NO. Could some of the investing public care - I think the odds are greater here. Have you read the article? The ending is so slanted that you gets the impression that MUSE has no effective patient base left and I know that you don't believe that. NO ONE go buy this issue. Read it from friends or at the library. Jim